ADAMTS-L2 inhibitors represent a specialized class of compounds that target the activity of the ADAMTS-like protein 2 (ADAMTS-L2). ADAMTS-L2 is a member of the ADAMTS (A Disintegrin and Metalloproteinase with Thrombospondin motifs) family, which is characterized by its unique combination of metalloproteinase and disintegrin domains. The ADAMTS family is primarily known for its involvement in the regulation of extracellular matrix (ECM) components, as these proteins cleave and modify ECM molecules such as proteoglycans, collagens, and other structural proteins. Inhibitors targeting ADAMTS-L2 specifically interact with its enzymatic domains, typically designed to block the zinc-binding motif within the metalloproteinase active site, which is essential for its catalytic function. These inhibitors tend to be highly selective, focusing on the active site configuration and the surrounding substrate recognition motifs to limit off-target effects and ensure the precise modulation of ADAMTS-L2 activity.
The regulation of ADAMTS-L2 by its inhibitors is important for maintaining the balance of ECM turnover and remodeling. The ECM is crucial for providing structural integrity and biochemical signals within tissues. By inhibiting ADAMTS-L2, these compounds can potentially influence processes such as collagen organization and proteoglycan breakdown, which are integral to tissue structure. Given that ADAMTS-L2 is also involved in various cellular processes like cell migration and adhesion, the inhibitors play a significant role in modulating these activities by controlling the proteolytic environment surrounding cells. The design of ADAMTS-L2 inhibitors often involves structural mimicry or small molecules that can effectively bind and block the active site, thus preventing the proteolytic cleavage of ECM components. Detailed understanding of ADAMTS-L2 structure, enzymatic kinetics, and substrate preferences is fundamental for optimizing inhibitor efficacy and specificity.
SEE ALSO...
Items 11 to 14 of 14 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
May decrease the expression of ADAMTS-L2 through the inhibition of transcription factors such as NF-κB and activator protein 1 (AP-1), leading to transcriptional repression. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Could lead to the downregulation of the expression of ADAMTS-L2 by inhibiting the activation of sirtuins and subsequent alterations in chromatin compaction and gene expression. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
By acting as a tyrosine kinase inhibitor, it could decrease the phosphorylation of proteins involved in cell signaling, leading to a reduction in the expression of ADAMTS-L2. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
May specifically target DNA methyltransferases, leading to hypomethylation of the ADAMTS-L2 promoter and a consequent decrease in gene expression. | ||||||